is ketamine contraindicated in pulmonary hypertension

The administration of ketamine in patients with pulmonary arterial hypertension (PAH) may be contraindicated. Typically, ketamine, used as an anesthetic, can influence blood pressure, thus necessitating cautious consideration in specific scenarios, including the presence of PAH.

Upon closer examination, several concerns arise: firstly, ketamine's potential to increase heart rate and blood pressure could exacerbate the cardiac workload in PAH patients, potentially worsening their condition. Secondly, given that cardiac function in PAH patients may already be impaired, ketamine-induced blood pressure fluctuations might adversely affect cardiac perfusion, heightening the risk of cardiovascular incidents. Moreover, ketamine's potential to induce respiratory depression could intensify symptoms of breathlessness in these patients. Lastly, other side effects of ketamine, such as psychological reactions, may become more complex in the context of PAH, demanding vigilant attention.

Consequently, the use of ketamine in patients with PAH should be guided by specialized medical professionals, with a rigorous evaluation of the risk-benefit ratio. Patients are advised to seek counsel from healthcare providers prior to using any medication and to adhere to their recommendations. Self-administration of medication is discouraged to prevent avoidable health risks.